Skip to content
Politically.com Search all
Menu

Final rule 2025-16037

Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Pharmacogenetic Assessment System

The Food and Drug Administration (FDA, the Agency, or we) is classifying the pharmacogenetic assessment system into class II (special controls). The special controls that apply to the device type are identified in this order and will be part of the codified language for classification of the pharmacogenetic assessment system. We are taking this action because we have determined that classifying the device into class II will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.

Source: FederalRegister.gov API v1Recently refreshed. Last successful refresh: 2026-07-31 22:49:02 UTC.

Source-supplied record

Document details

Document number
2025-16037
Published
Aug 21, 2025
Effective
Aug 21, 2025
Comments close
Not supplied
Federal Register citation
90 FR 40704

Docket identifiers

  • Docket No. FDA-2025-N-2219

CFR references

  • Title 21, part 862